Dactinomycin Actinomycin D

Dactinomycin (also known generically as Actinomycin D) is the most significant member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces. As one of the older chemotherapy drugs, it has been used for many years. Actinomycin D was the first antibiotic shown to have anti-cancer activity. It was first isolated by Selman Waksman and his co-worker H. B. Woodruff in 1940. It was approved by the US FDA on December 10, 1964 and launched by Merck Sharp and Dohme under the trade name Cosmegen.

1: Weaver MS, Navid F, Huppmann A, Meany H, Angiolillo A. Vincristine and Dactinomycin in Infantile Myofibromatosis With a Review of Treatment Options. J Pediatr Hematol Oncol. 2014 Nov 11. [Epub ahead of print] PubMed PMID: 25389917.

2: Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DS. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol. 2014 Nov 1;32(31):3547-52. doi: 10.1200/JCO.2014.55.6787. Epub 2014 Sep 29. PubMed PMID: 25267746; PubMed Central PMCID: PMC4209105.